Hopstem's abstract on "The Preclinical and First-in-Human Study of iPSC Derived Human Forebrain Neural Progenitor Cell Injection-hNPC01 in Treating Chronic Ischemic Stroke" was selected as one of the prestigious Late-Breaking Poster Presentations at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) which to be held in Baltimore from May 7 to May 11, 2024. Among thousands of abstracts, only 50 were chosen for this category.
In addition to this exciting news, Dr. Jing Fan, the founder of Hopstem, has been recommended by her peers to serve as a new member of the ASGCT Stem Cell Committee. Dr. Fan's appointment, with a term of three years, involves collaborating with other committee members in planning the annual forum and educational columns for the Stem Cell Committee. This role aims to foster advancements and promote the forefront of stem cell research.
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
Hopstem hNPC01 Earns FDA RMAT Designation for Chronic Stroke Therapy
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
Hopstem Announces FDA Granted iPSC Therapy hNPC01 Injection Fast Track Designation, Accelerating Global Breakthrough in Treatment of Cerebral Neural Injury Diseases
R&D Center: Building 11,Heda Medicine Valley V, Qiantang Area,
Hangzhou, Zhejiang, China
Manufacturing Center: 3rd & 4th Floor, Building 10,Heda Medicine Valley lll,
Qiantang Area, Hangzhou, Zhejiang, China
U.S. Office: 103 Carnegie center, Suite 300, Princeton,
NJ 08540, USA
